Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT01365481
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT01365481 -
2009-017594-37
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Colombia, Finland, Germany, Guatemala, Philippines, Poland, Romania, Russia, Singapore, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01365481. Allocation not applicable; no masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-04-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
- Condition
- Hypertension
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Valsartan
- Intervention (Drug)
- amlodipine
- Intervention (Drug)
- Hydrochlorothiazide
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01365481- Content hash
a1308fabea31a443b3ddaf991efced5a5ca4fd1273d41f88198a3ab7e8012e9e